Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma

NCT05182073 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT05182073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05182073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Fate Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 10, 2021
Completion date
October 18, 2024
Enrollment
31 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, myeloma